Dewpoint Therapeutics has lined up another Big Pharma partner, this time Danish drugmaker Novo Nordisk, in a bet that its strategy of going after molecular clusters known as condensates could have an impact on insulin resistance and diabetic complications.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,